in the name of god chronic renal failure by: dr. shahram ala (pharmd, bcps)
TRANSCRIPT
In the name of GodIn the name of God
Chronic Renal Chronic Renal FailureFailure
By: By:
Dr. Shahram AlaDr. Shahram Ala
(PharmD, BCPS)(PharmD, BCPS)
KidneyKidney
Each kidney has about 1 million Each kidney has about 1 million nephronsnephrons Receives 25% 0f GFR (1200 ml/min, > Receives 25% 0f GFR (1200 ml/min, >
1700 lit/d)1700 lit/d) 1-1.5 lit urine (waste products & excess 1-1.5 lit urine (waste products & excess
water)water) Reabsorption of sodium, glucose, waterReabsorption of sodium, glucose, water Secretion of urea, Cr, K+, H+, Secretion of urea, Cr, K+, H+,
phosphate phosphate
Other functions of Other functions of kidneyskidneys
Renin secretionRenin secretion
Erythropoietin secretionErythropoietin secretion
Activation of vit D3 (Calcitriol)Activation of vit D3 (Calcitriol)
Renal FailureRenal Failureup to 75% of function can be lost before up to 75% of function can be lost before
it is noticeableit is noticeable
ARF:ARF: Rapid Rapid onset, usually onset, usually reversible, rapid reversible, rapid reduction in reduction in urine volumeurine volume
CRF:CRF: Slow Slow onset, onset, progressive, is progressive, is not reversiblenot reversible
Treatment Modalities Treatment Modalities
HemodialysisHemodialysis Peritoneal DialysisPeritoneal Dialysis Renal TransplantRenal Transplant
In 1950s, Life expectancy of ESRD In 1950s, Life expectancy of ESRD patients was just a few days to weekspatients was just a few days to weeks
CRF & ESRDCRF & ESRD
CRF and ESRD are significant CRF and ESRD are significant causes of morbidity & mortalitycauses of morbidity & mortality
Analgesic NephropathyAnalgesic Nephropathy Tubulointerstitial renal diseaseTubulointerstitial renal disease (Papillary necrosis and (Papillary necrosis and
interstitial nephritis) due to ingestion of a mixture of 2 interstitial nephritis) due to ingestion of a mixture of 2 analgesics usually with codeine or caffeineanalgesics usually with codeine or caffeine
More prevalent in More prevalent in femalesfemales (5-7.1 times) with peak (5-7.1 times) with peak incidence between 4incidence between 4thth and 5 and 5thth decade decade
Salt-wasting nephropathy, ↓urine concentrating & Salt-wasting nephropathy, ↓urine concentrating & acidifying capacityacidifying capacity
Symptoms:Symptoms: flank pain, pyuria, hematuria, urethral flank pain, pyuria, hematuria, urethral obstructionobstruction
Mechanism:Mechanism: oxidative metabolite of oxidative metabolite of acetaminophen beside reduced acetaminophen beside reduced glutathione capacity (due to ASA)glutathione capacity (due to ASA)
Management:Management: abstinence from abstinence from NSAIDs & combination analgesics, NSAIDs & combination analgesics, high fluid intake (if possible), high fluid intake (if possible), management of ESRD is similar to management of ESRD is similar to other causesother causes
Analgesic Nephropathy Analgesic Nephropathy (cont.)(cont.)
Medication UseMedication Use Both HD & PD patients receive a median Both HD & PD patients receive a median
of 8 different drugs including:of 8 different drugs including: Antihypertensives (CCBs, ACEIs)Antihypertensives (CCBs, ACEIs) Antidiabetic agentsAntidiabetic agents ErythropoietinErythropoietin Phosphate-binding agentsPhosphate-binding agents MultivitaminsMultivitamins Vit D supplementsVit D supplements ASA ASA AnalgesicsAnalgesics GI agentsGI agents WarfarinWarfarin
Nonadherence & drug-related problemsNonadherence & drug-related problems
General feature in CRFGeneral feature in CRF Most patients are symptom free until Most patients are symptom free until
renal function is <25% normalrenal function is <25% normal
At renal function <10% normal, uremic At renal function <10% normal, uremic symptoms occurssymptoms occurs
At renal function<5%, dialysis or At renal function<5%, dialysis or transplant is requiredtransplant is required
Intact nephron hypothesisIntact nephron hypothesis
PathogenesisPathogenesis
Glomerular capillary hypertensionGlomerular capillary hypertension
Microalbuminuria or proteinuria Microalbuminuria or proteinuria
Increased renal plasma flow Increased renal plasma flow (with high Pr (with high Pr Intake)Intake)
Dyslipoproteinemia (esp. TG-rich apo-B-Dyslipoproteinemia (esp. TG-rich apo-B-lipoproteins)lipoproteins)
Clinical assessmentClinical assessment
Evaluation of renal functionEvaluation of renal function BUN, SrCrBUN, SrCr Clcr= (140-Age)BW/72*SrCr (*%85 for Females)Clcr= (140-Age)BW/72*SrCr (*%85 for Females) Clcr based on urine collection and measurement of Clcr based on urine collection and measurement of
UCrUCr Due to TS of creatinine in renal dysfunction, Clcr Due to TS of creatinine in renal dysfunction, Clcr
overestimates the GFRoverestimates the GFR
Proteinuria (Alb, Alb/Cr Ratio)Proteinuria (Alb, Alb/Cr Ratio) Microalbuminuria: 30-300 mg/24hMicroalbuminuria: 30-300 mg/24h Overt proteinuria: >300 mg/24hOvert proteinuria: >300 mg/24h
Dipstick test (Reagent strips) Dipstick test (Reagent strips) Alb/Cr : 30-300 µg/mg (Microalbuminuria)Alb/Cr : 30-300 µg/mg (Microalbuminuria)
PreventionPrevention
AntihypertensivesAntihypertensives
Dietary Protein RestrictionDietary Protein Restriction
Treatment of DyslipoproteinemiaTreatment of Dyslipoproteinemia
Intensive Glu Control (in Diabetic Intensive Glu Control (in Diabetic patients)patients)
HTN is both a cause and a result of RFHTN is both a cause and a result of RF
HTN causes glumerolar hyperperfusion HTN causes glumerolar hyperperfusion leading to progressive renal damageleading to progressive renal damage
Goal of BP: Goal of BP: 130/85 (in patients with some degree of renal 130/85 (in patients with some degree of renal
failure) failure) 125/75 (in patients with proteinuria >1gr)125/75 (in patients with proteinuria >1gr)
HTN & CRFHTN & CRF
Prevention:Prevention:Which Antihypertensives?Which Antihypertensives?
ACEIs ACEIs (Enalapril, Captopril, Lisinopril) (Enalapril, Captopril, Lisinopril) Ag II play a central role in glomerular capillary Ag II play a central role in glomerular capillary
pressure pressure ARAsARAs (Losartan, Irbesartan, Valsartan, Candesartan, (Losartan, Irbesartan, Valsartan, Candesartan,
Eprosartan, Telmisartan)Eprosartan, Telmisartan)
CCBsCCBs (Diltiazem, Verapamil are superior to (Diltiazem, Verapamil are superior to Nifedipine)Nifedipine) Effects on renal hemodynamic, Effects on renal hemodynamic,
cytoprotective & antiproliferative propertiescytoprotective & antiproliferative properties ACEIs+CCBsACEIs+CCBs
Prevention:Prevention: Dietary Protein Restriction Dietary Protein Restriction
There is an association between There is an association between “Protein“Protein ingestion”ingestion” & &“GFR”“GFR” and and “Renal Plasma Flow”“Renal Plasma Flow”
For GFR>25 or in Diabetics → 0.6-0.8 g/kg/dayFor GFR>25 or in Diabetics → 0.6-0.8 g/kg/day
GFR<25 or in Diabetics with RF → 0.3-0.6 GFR<25 or in Diabetics with RF → 0.3-0.6 g/kg/dayg/kg/day
Protein restriction may delay development of ESRD, Protein restriction may delay development of ESRD, but no definitive conclusions could be madebut no definitive conclusions could be made
Prevention:Prevention:Treatment of Treatment of
DyslipoproteinemiaDyslipoproteinemia ↑↑TG (Up to 70% of patients), ↓HDL, ↔ Total-CTG (Up to 70% of patients), ↓HDL, ↔ Total-C
Progression of renal diseaseProgression of renal disease Cardiovascular morbidity & mortalityCardiovascular morbidity & mortality
Treatment:Treatment: Based on individual lipid profile, generally Based on individual lipid profile, generally
NCEP guidelines are used NCEP guidelines are used
Gemfibrozil (Clofibrate accumulates in CRF)Gemfibrozil (Clofibrate accumulates in CRF) StatinesStatines
ESRDESRD Uremic Toxins:Uremic Toxins:
urea, guanidine, purine & pyridine urea, guanidine, purine & pyridine derivatives, aliphatic & aromatic amines, derivatives, aliphatic & aromatic amines, PTHPTH
Secondary Complications:Secondary Complications: Mild Renal Dysfunction:Mild Renal Dysfunction: fluid overload, HTNfluid overload, HTN Mod to Severe Renal Dysfunction:Mod to Severe Renal Dysfunction: ↑ ↑ K, ↑ P, ↓Ca, Metabolic acidosis, K, ↑ P, ↓Ca, Metabolic acidosis, AnemiaAnemia
Metabolic Effects of Metabolic Effects of UremiaUremia
Fluid/Electrolytes/Acid-Base:Fluid/Electrolytes/Acid-Base: Fluid retention, ↑K, ↑Mg, ↑P, ↓Ca, Metabolic acidosisFluid retention, ↑K, ↑Mg, ↑P, ↓Ca, Metabolic acidosis
Hematologic:Hematologic: Anemia, Hemostatic abnorm., Immune suppresionAnemia, Hemostatic abnorm., Immune suppresion
CVS:CVS: HTN, CHF, Pericarditis, Atherosclerosis, Arrhytmia, HTN, CHF, Pericarditis, Atherosclerosis, Arrhytmia, ↓ ↓ exercise tolerance exercise tolerance
Endocrine:Endocrine: Hyperpara, Altered thyroid function, Hypophyseal-Hyperpara, Altered thyroid function, Hypophyseal-
gonadal dysfunc, Erythropoietin deficiencygonadal dysfunc, Erythropoietin deficiency
Metabolic Effects of Uremia Metabolic Effects of Uremia (Cont.)(Cont.) GI:GI:
Anorexia, Nausea, Vomiting, Delayed gastric emptying, Ulcers, GI Anorexia, Nausea, Vomiting, Delayed gastric emptying, Ulcers, GI bleedingbleeding
Musculoskeletal:Musculoskeletal: Renal bone disease, Amyloidosis, Extraskeletal calcificationRenal bone disease, Amyloidosis, Extraskeletal calcification
Neurologic:Neurologic: Lethargy, Tremor, Asterixix, Cramp, Motor weakness, Peripheral Lethargy, Tremor, Asterixix, Cramp, Motor weakness, Peripheral
neuropathyneuropathy
Skin:Skin: Altered pigmentation, PruritusAltered pigmentation, Pruritus
Psychologic:Psychologic: Depression, Anxiety, Psychosis Depression, Anxiety, Psychosis
PharmacotherapyPharmacotherapy
To Slow the rate of progressionTo Slow the rate of progression
To manage secondary complicationsTo manage secondary complications